B-cell Non-Hodgkin's Lymphoma Clinical Trial
Official title:
A Phase Ib/IIa Clinical Study of IMM0306 fo r Injection in Combination With Lenalidomide for the Treatment of Relapsed/Refractory CD20-Positive B-Cell Non-Hodgkin's Lymphoma Cell Non-Hodgkin's Lymphoma
The objective of this study was to evaluate the safety and efficacy of IMM0306 in combination with lenalidomide in patients with relapsed/refractory CD20-positive B-cell non-Hodgkin lymphoma.
Main study purpose: To assess the safety and tolerability of IMM0306 in combination with lenalidomide to determine the maximum tolerated dose (MTD) (if available) and the recommended Phase 2 dose (RP2D). Secondary study purpose 1. To assess the antitumor efficacy of IMM0306 in combination with lenalidomide. 2. To assess the immunogenicity of IMM0306 in combination with lenalidomide. 3. To evaluate the pharmacokinetic (PK) profile of IMM0306 in combination with lenalidomide. Exploratory study purpose: 1. Explore the correlation between exposure to IMM0306 and efficacy and safety (data permitting). 2. Explore the correlation of biomarkers with safety. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00588094 -
Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL
|
Phase 2 | |
| Not yet recruiting |
NCT05091541 -
A Phase 1/2 Study of CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03639181 -
Clinical Trial in Chinese Patients of B-cell Non-Hodgkin's Lymphoma(GB226)
|
Phase 2 | |
| Recruiting |
NCT06104553 -
A Trial of SHR-A1912 Combined With Other Therapies in B-cell Non-Hodgkin 's Lymphoma
|
Phase 1/Phase 2 | |
| Terminated |
NCT01352312 -
Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma
|
Phase 1 | |
| Not yet recruiting |
NCT06314828 -
A Tolerability, Safety and Efficacy Study of RJMty19 in Subjects With Relapsed or Refractory B-NHL
|
Phase 1 | |
| Enrolling by invitation |
NCT05332054 -
Long-Term Follow-up Study
|
||
| Suspended |
NCT04697290 -
CD19/CD20 Dual-CAR-T in B-cell Non-Hodgkin's Lymphoma Patients.
|
Early Phase 1 | |
| Completed |
NCT02564744 -
Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHL
|
Phase 2 | |
| Recruiting |
NCT05453669 -
Clinical Study of the Efficacy of CD19-CAR-DNT Cells in the Treatment of Relapsed/Refractory B-cell NHL
|
Phase 1 | |
| Recruiting |
NCT05190068 -
HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
|
Phase 1 | |
| Suspended |
NCT04746131 -
Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL)
|
Phase 1 | |
| Active, not recruiting |
NCT00927797 -
Interventional Study on Pentostatin, Cyclophosphamide and Rituximab in Indolent B-Cell Non-Hodgkin-Lymphoma (B-NHL)
|
Phase 2 | |
| Recruiting |
NCT05436223 -
Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma
|
Phase 2 | |
| Completed |
NCT00457782 -
A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's Lymphoma
|
Phase 1 | |
| Not yet recruiting |
NCT03105596 -
Chidamide Plus DICE Regimen for Patients With Relapse or Refractory B-cell Non-Hodgkin's Lymphoma (NHL)
|
Phase 2 |